Defining the Inflammatory Plasma Proteome in Pediatric Hodgkin Lymphoma

Hodgkin lymphoma (HL) histopathology is characterized by rare malignant Reed-Sternberg cells among an inflammatory infiltrate. We hypothesized that characteristics of inflammation in pediatric HL lesions would be reflected by the levels of inflammatory cytokines or chemokines in pre-therapy plasma o...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancers 2020-12, Vol.12 (12), p.3603
Hauptverfasser: Agrusa, Jennifer E, Scull, Brooks P, Abhyankar, Harshal A, Lin, Howard, Ozuah, Nmazuo W, Chakraborty, Rikhia, Eckstein, Olive S, Gulati, Nitya, Fattah, Elmoataz Abdel, El-Mallawany, Nader K, Rouce, Rayne H, Dreyer, ZoAnn E, Brackett, Julienne, Margolin, Judith F, Lubega, Joseph, Horton, Terzah M, Bollard, Catherine M, Gramatges, M Monica, Kamdar, Kala Y, McClain, Kenneth L, Man, Tsz-Kwong, Allen, Carl E
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Hodgkin lymphoma (HL) histopathology is characterized by rare malignant Reed-Sternberg cells among an inflammatory infiltrate. We hypothesized that characteristics of inflammation in pediatric HL lesions would be reflected by the levels of inflammatory cytokines or chemokines in pre-therapy plasma of children with HL. The study objectives were to better define the inflammatory pre-therapy plasma proteome and identify plasma biomarkers associated with extent of disease and clinical outcomes in pediatric HL. Pre-therapy plasma samples were obtained from pediatric subjects with newly diagnosed HL and healthy pediatric controls. Plasma concentrations of 135 cytokines/chemokines were measured with the Luminex platform. Associations between protein concentration and disease characteristics were determined using multivariate permutation tests with false discovery control. Fifty-six subjects with HL (mean age: 13 years, range 3-18) and 47 controls were analyzed. The cytokine/chemokine profiles of subjects with HL were distinct from controls, and unique cytokines/chemokines were associated with high-risk disease (IL-10, TNF-α, IFN-γ, IL-8) and slow early response (CCL13, IFN-λ1, IL-8). TNFSF10 was significantly elevated among those who ultimately relapsed and was significantly associated with worse event-free survival. These biomarkers could be incorporated into biologically based risk stratification to optimize outcomes and minimize toxicities in pediatric HL.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers12123603